Bifogade filer
Kurs
-0,32%
Likviditet
0,05 MSEK
Kalender
| Est. tid* | ||
| 2026-05-27 | N/A | Årsstämma |
| 2026-05-08 | N/A | X-dag ordinarie utdelning ACUC 0.00 SEK |
| 2026-04-28 | 08:30 | Kvartalsrapport 2026-Q1 |
| 2026-02-20 | - | Bokslutskommuniké 2025 |
| 2025-11-14 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-19 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-13 | - | X-dag ordinarie utdelning ACUC 0.00 SEK |
| 2025-05-12 | - | Årsstämma |
| 2025-05-08 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-21 | - | Bokslutskommuniké 2024 |
| 2024-12-19 | - | Extra Bolagsstämma 2024 |
| 2024-11-29 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-05 | - | X-dag ordinarie utdelning ACUC 0.00 SEK |
| 2024-06-04 | - | Årsstämma |
| 2024-04-26 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-16 | - | Bokslutskommuniké 2023 |
| 2023-11-30 | - | Kvartalsrapport 2023-Q3 |
| 2023-10-02 | - | Extra Bolagsstämma 2023 |
| 2023-08-31 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-05 | - | X-dag ordinarie utdelning ACUC 0.00 SEK |
| 2023-05-04 | - | Årsstämma |
| 2023-04-28 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-24 | - | Bokslutskommuniké 2022 |
| 2022-11-11 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-12 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-06 | - | X-dag ordinarie utdelning ACUC 0.00 SEK |
| 2022-05-04 | - | Årsstämma |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-11-12 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-11 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-29 | - | X-dag ordinarie utdelning ACUC 0.00 SEK |
| 2021-04-28 | - | Årsstämma |
| 2021-04-28 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-13 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-28 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-13 | - | X-dag ordinarie utdelning ACUC 0.00 SEK |
| 2020-05-12 | - | Årsstämma |
| 2020-05-12 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-25 | - | Bokslutskommuniké 2019 |
| 2019-11-19 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-16 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-17 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-26 | - | X-dag ordinarie utdelning ACUC 0.00 SEK |
| 2019-04-25 | - | Årsstämma |
| 2019-02-13 | - | Bokslutskommuniké 2018 |
| 2018-11-22 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-31 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-25 | - | Kvartalsrapport 2018-Q1 |
| 2018-03-22 | - | X-dag ordinarie utdelning ACUC 0.00 SEK |
| 2018-03-21 | - | Årsstämma |
| 2018-02-06 | - | Bokslutskommuniké 2017 |
| 2017-11-09 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-30 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-15 | - | Kvartalsrapport 2017-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
AcuCort has published its newsletter for March 2026. The newsletter features a CEO statement by Jonas Jönmark as well as two articles: one on the company now operating its pharmacovigilance system in-house, and one on Zeqmelits® being suitable for more indications than acute allergic reaction, where AcuCort sees opportunities primarily within two areas.
The newsletter is available here: https://bit.ly/acucort-spring-2026
For further information:
Jonas Jönmark, CEO, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.